Project Grant R21AI182709
Award Date
4/11/25
Completion Date
3/31/27
Dollars Obligated
$238K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60612, USA
Similar Awards
This $802,798 federal Project Grant was awarded on July 2, 2024 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports the development of a novel class of antibiotics called Biamyxins (BMX) that target multidrug-resistant Gram-negative bacterial infections, which are a leading cause of healthcare-associated infections (HAIs) in the U.S. The goal is to identify a lead development candidate...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $2,308,174 to the University of Florida to conduct research on translating new antimicrobial agents and combination therapies to combat drug-resistant Gram-negative pathogens like Acinetobacter baumannii and Klebsiella pneumoniae. The key objectives are to generate mechanistic insights into antibiotic resistance,...
This $595,901 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to expand the understanding of biosynthetic mechanisms for natural antimicrobial peptides (AMPs). The overarching goal is to dissect the mechanisms of a novel biosynthetic gene cluster (BGC) that leads to AMP production, with a focus on ascribing roles of the BGC components in both the biosynthetic events yielding...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,444,195 to the University of Connecticut Health Center to conduct research aimed at enhancing the efficacy of topoisomerase inhibitors against antibiotic-resistant bacteria such as Escherichia coli and Pseudomonas aeruginosa. The research seeks to discover metabolites that can modulate bacterial persistence and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $661,387.00 to Emory University to conduct research on the regulation and mechanism of RND-mediated antibiotic efflux in Pseudomonas bacteria. The goal is to generate a comprehensive understanding of the MexXY-OprM efflux system, including the molecular basis of gene regulation and substrate selection, in order to...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,379,734 to the University of Texas at Austin to conduct research on microcins - a class of antibacterial proteins. The project aims to study the sequence variation and antimicrobial activity of microcins, with the goal of identifying new strategies to overcome the outer membrane permeability barrier of Gram-negative...
The federal Project Grant award R01AI187556 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $749,417.00 in funding to President and Fellows of Harvard College from November 2024 through October 2029. The research project aims to synthesize and evaluate novel antibiotic compounds targeting the lipoprotein transport pathway in Gram-negative bacteria, including multidrug-resistant E. coli and K....
This $175,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, aims to develop a decentralized antimicrobial resistance (AMR) surveillance system for resource-limited settings. The key objectives are to assess the cost-effective detection of drug-resistant bacteria and antimicrobial bacteriophages using long-read sequencing technology, with a focus on Pseudomonas aeruginosa...
This $195,625 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to structurally and functionally characterize phosphoethanolamine (PEtN) transferase enzymes that modify bacterial lipid A, resulting in resistance to cationic antimicrobial peptides like colistin. The research aims to develop inhibitory strategies and quantitative in vitro assays to evaluate inhibitors...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $948,482 to the University of Colorado-Denver to study the molecular mechanisms of the YbtPQ siderophore importer in antibiotic-resistant bacterial infections. The 5-year award, beginning on July 17, 2024, aims to define the substrate selectivity and inhibitory mechanisms of YbtPQ, as well as understand its...